Deltis Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 1.50 M
- Company Age 4 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -34.40%
- Profit Growth -1049.44%
- Ebitda 1397.61%
- Net Worth -84.02%
- Total Assets -31.38%
About Deltis Pharma
Deltis Pharma Private Limited (DPPL) is a Private Limited Indian Non-Government Company incorporated in India on 02 July 2020 (Four years and seven months 3 days old ). Its registered office is in Ambala, Haryana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M, as per Ministry of Corporate Affairs (MCA) records.
Vashist Sandhu and Sher Singh serve as directors at the Company.
Company Details
-
Location
Ambala, Haryana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24304HR2020PTC087164
-
Company No.
087164
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
02 Jul 2020
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Deltis Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vashist Sandhu
|
Director | 05-Feb-2021 | Current |
|
Sher Singh
|
Director | 20-Apr-2022 | Current |
Financial Performance of Deltis Pharma.
Deltis Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 34.4% decrease. The company also saw a substantial fall in profitability, with a 1049.44% decrease in profit. The company's net worth observed a substantial decline by a decrease of 84.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Deltis Pharma?
Unlock access to Deltis Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Vaxova Drugs Private LimitedVashist Sandhu is a mutual person
-
Alfavision Biotech Private LimitedVashist Sandhu is a mutual person
-
Aconwell Pharma Private Limited
Vashist Sandhu is a mutual person
-
Vaxova Life Sciences Private Limited
Vashist Sandhu is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Deltis Pharma?
Deltis Pharma has a workforce of 0 employees as of Apr 11, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Deltis Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Deltis Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
